Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Subjects With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs JNJ 54175446 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 27 Jun 2017 Status changed from recruiting to completed.
- 20 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
- 07 Nov 2016 Status changed from not yet recruiting to recruiting.